胆囊神经内分泌肿瘤与177Lu DOTATATE:生长抑素受体高表达但无临床缓解
本文报道一例74岁男性复发性WHO 3级胆囊神经内分泌肿瘤(GB-NET),68Ga DOTATATE PET/CT显示高生长抑素受体表达,但177Lu DOTATATE治疗未能控制肝转移灶,最终终止治疗,提示GB-NET中SSTR阳性显像并不总带来177Lu DOTATATE的良好治疗反应。
要点
- 胆囊神经内分泌肿瘤罕见,占所有NETs不足0.5%,其SSTR表达及靶向治疗反应知之甚少。
- 68Ga DOTATATE PET/CT是评估SSTR表达和制定177Lu DOTATATE治疗计划的有价值影像手段。
- 本例WHO 3级GB-NET肝转移灶DOTATATE摄取高,但177Lu DOTATATE未能控制肝转移,治疗终止。
核心结论
- GB-NET中阳性SSTR显像并不总是带来177Lu DOTATATE的良好治疗反应。
研究设计与样本
- 本文为病例报告,报道一例74岁男性复发性WHO 3级胆囊神经内分泌肿瘤患者。
主要发现
- 该患者肝转移灶DOTATATE摄取高,但177Lu DOTATATE治疗未能控制肝转移。
- 因177Lu DOTATATE未能控制肝转移,治疗被终止。
关键数值与推荐
- 胆囊神经内分泌肿瘤占所有NETs不足0.5%。
- 68Ga DOTATATE PET/CT用于评估SSTR表达和177Lu DOTATATE治疗计划。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gallbladder neuroendocrine tumors (GB-NETs) are rare, accounting for <0.5% of all NETs, and little is known about somatostatin receptor expression (SSTR) and its response to SSTR-targeted treatment such as Lutetium-177 ( 177 Lu) DOTATATE. 68 Ga DOTATATE PET/CT is a valuable imaging modality for SSTR expression and 177 Lu DOTATATE treatment planning. We present a case of a 74-year-old man with recurrent WHO grade 3 GB-NET. 177 Lu DOTATATE failed to control hepatic metastases despite high DOTATATE uptake, which led to treatment discontinuation. This case highlights the fact that positive SSTR imaging in GB-NETs does not always lead to a favorable response to 177 Lu DOTATATE.
引用
- Aksakal M, Liu Y, Chen DL, et al. Gallbladder Neuroendocrine Tumor and 177 Lu DOTATATE: High Somatostatin Receptor Expression Without Clinical Response. Clin Nucl Med. 2025. PMID: 40472258. doi:10.1097/RLU.0000000000006001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。